Acetylcysteine injection - Cumberland Pharmaceuticals

Next Previous
Drug Profile

Acetylcysteine injection - Cumberland Pharmaceuticals

Alternative Names: N-acetylcysteine (NAC) injection - Cumberland Pharmaceuticals; Acetadote; Intravenous NAC - Cumberland Pharmaceuticals

Latest Information Update: 09 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cumberland Pharmaceuticals
  • Developer Al-Nabil; Cumberland Pharmaceuticals; GerminMED; Harbin Gloria Pharmaceuticals
  • Class Antibronchitics; Antidotes; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants; Free radical inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Poisoning
  • New Molecular Entity No

Highest Development Phases

  • Marketed Poisoning
  • Phase II Kidney disorders
  • Discontinued Liver failure

Most Recent Events

  • 04 Jan 2018 Phase II development is ongoing in Kidney disorders (Prevention) in USA
  • 04 Jan 2018 Cumberland Pharmaceuticals completes a phase II trial in Kidney disorders (Prevention) in USA (IV) (NCT00780962)
  • 11 Sep 2017 Discontinued - Preregistration for Liver failure in USA (IV), because no recent reports identified after the US FDA issued a complete response letter
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top